SNIPR Biome Receives CARB-X Funding to Test...
CMN Briefs
Apr. 22, 2024
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Sumitomo Pharma
Main (gene editing) focus: Undisclosed
Company stage: Commercial
Diseases: Undisclosed
Genome editing tool: CRISPR-Cas9
Funding stage: Public (OTC:DNPUF)
Location: Osaka, Osaka, Japan
Website: https://www.sumitomo-pharma.com/
Pipeline: https://www.sumitomo-pharma.com/rd/clinical/pipeline.html
Partners: ERS Genomics
Sumitomo Pharma is a Japan-based company with global operations. The company is mainly involved in the gene-editing space through its license agreement with ERS Genomics, which it entered into in April 2022. The lead gene-editing programmes coming from the license agreement are yet to be disclosed.
